DECEMBER 2024
TREAT-AD Nominations
A new version of nominated targets has been released. This release includes 29 AD target nominations from TREAT-AD consortium researchers.
Protein information
Gene-specific pages now display the primary Uniprot accession number and Pharos class value. The Unpirot accession number links to the corresponding protein's UniprotKB page, which includes information about any secondary accessions that represent alternate protein isoforms associated with the gene.
Resources
The gene-specific Resources tab now includes a Drug Development Resource section, as well as new Additional Resource links to SEA-AD snRNAseq results, UniProtKB, AlzForum, AlzPED, and GeneCards.
MAY 2024
Targeted SRM Proteomic Evidence
Targeted Selected Reaction Monitoring (SRM) results for differential protein expression between AD cases and controls are now available in the Gene Comparison Tool, and on the gene-specific Protein Evidence tabs.
Enhanced Ensembl Information
Gene-specific overview content now includes Ensembl permalinks and Ensembl release versions, as well as possible replacement values and ID History links for retired Ensembl Gene IDs.
Resources
The gene-specific Resources tab now includes links to relevant information in the AMP-PD Target Explorer, a resource for exploring nominated targets implicated in Parkinson's Disease.
DECEMBER 2023
Nominated Targets
A new version of nominated targets has been released. This release includes over 900 nominated targets submitted by researchers from the AMP-AD, Resilience-AD, and TREAT-AD consortiums, and by non-consortium contributors from the AD research community.
NOVEMBER 2023
TREAT-AD Nominations
A new version of nominated targets has been released. This release includes 78 new AD targets nominated by TREAT-AD consortium researchers.
Target Enabling Resources
Information about TREAT-AD Target Enabling Resources has been integrated into Agora. Genes that have been selected for Target Enabling Resource development are highlighted, and a new Target Enabling Resources section has been added to the Resources tab. The new section is visible only for genes that have been selected for experimental reagent support, and contains links to further information about the experimental reagents that are currently available, under development, or planned. You can also filter the Gene Comparison Tool to display targets that have been selected for experimental reagent support.
Resources
Links to dementia-related publication information on PubAD have been updated.
JULY 2023
AD Biological Domain Mappings
Gene-specific AD Biological Domain Mappings have been introduced. You can view a gene's linked Biological Domains on the Summary tab, and you can filter genes by linked Biological Domains in the Gene Comparison Tool.
AD Risk Scores
The TREAT-AD Consortium Target Ranking Scores have been replaced with AD Risk Scores. You can view a gene's AD Risk Scores on the Summary tab, and you can sort genes by their AD Risk Scores in the Gene Comparison Tool.
EQTL Summary Evidence
The Summary of Evidence values for EQTL have been refreshed; you can view a gene's Summary of Evidence values on the Summary tab.
JANUARY 2023
Genetic Association with LOAD
The Genetic Association with LOAD summary information has been refreshed using evidence from multiple studies compiled by the
ADSP Gene Verification Committee.
Available Genes
Information and results are now available for additional genes.
DECEMBER 2022
TMT Evidence
Tandem mass tagged (TMT) spectrometry results for differential protein expression between AD cases and controls are now available.
SEPTEMBER 2022
TREAT-AD Scores
The TREAT-AD score plots presented on the Summary tab have been corrected to properly align with the underlying score distributions. Gene scores have not been modified by this correction.
JULY 2022
Gene Comparison Tool
A new Gene Comparison Tool has been introduced, enabling the visual comparison of RNA and Protein differential expression evidence across multiple potential AD targets. You can use this interface to sort, filter, and search for genes to build custom result sets to explore their relationships and to evaluate hypotheses.
TREAT-AD Nominations
A new version of nominated targets has been released. This release includes seven new AD targets nominated by TREAT-AD consortium researchers.
JUNE 2022
Evidence
Evidence plots can now be downloaded as JPEG or PNG image files.
MAY 2022
RNASeq Expression
RNA Expression plots now display the results of a modified differential expression analysis workflow. Additional ROSMAP study data was incorporated, and RNASeq data from all contributing studies was realigned, renormalized, and then differential expression was calculated. RNASeq gene coexpression networks will be updated using the results of the new analysis in a subsequent release.
MARCH 2022
Nominated Targets
A new version of nominated targets has been released. This release includes over 600 nominated targets submitted by AMP-AD consortium researchers, and by non-consortium contributors from the AD research community.
Summary Information
TREAT-AD Consortium target ranking scores have been updated; the methodology used to calculate the Genetics Score has been modified.
FEBRUARY 2022
Additional Resources
Links to dementia-related publication information on PubAD are available.
DECEMBER 2021
Summary Information
Plots depicting
TREAT-AD Consortium target ranking scores and score distributions are now available.
JUNE 2021
Nominated Targets
A new version of nominated targets has been released.
Experimental Validation Details
Nominating teams have provided details on experimental validation studies they performed to examine a role for the target in AD.
JULY 2020
RNA Evidence
A plot that depicts associations between gene expression levels and clinical and neuropathology phenotypes is now available.
MARCH 2020
Druggability Information
A new version of druggability classifications has been incorporated.
JULY 2019
Druggability Information
Druggability buckets have been updated with two additional categories: antibody feasibility and safety.
Proteomic Data
Differential protein expression between AD cases and controls is now available.
Metabolomic Data
Differential abundance of metabolites between AD cases and controls is now available.
JUNE 2019
Nominated Targets
Researchers outside the AMP-AD consortium have submitted nominated targets.
Druggability Information
Small Molecule Druggability is now available for all genes across the genome.
MAY 2019
Nominated Targets
The total number of AMP-AD nominated targets has increased to 500 targets.
MARCH 2019
Transcriptomic Data
Differential expression from RNAseq is now available for all genes with measurable expression across the genome.
